Thioprine (Azathioprine) 50mg Film-Coated Tablet, 10×10’s Blister Pack
Prevent rejection of kidney transplants and treat severe rheumatoid arthritis, which does not respond to conventional treatment.
Share Now
Additional Information
Name | Thioprine |
Description | Azathioprine is an imidazole derivative of 6-mercaptopurine (6-MP). It is rapidly broken down in vivo into 6-MP and 1-methyl-4-nitro-5-thioimidazole. 6-MP readily crosses cell membranes and is converted intracellularly into a number of purine thioanalogues, which include the main active nucleotide, thioinosinic acid. The activity of the methylnitroimidazole moiety has not been defined clearly. However, in various systems it appears to modify the activity of azathioprine compared with that of 6-MP. |
Active Ingredient | Azathioprine |
Indication | Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basic immunosuppression). Azathioprine is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung, or pancreas transplants. Azathioprine is indicated either alone or in combination with corticosteroids and/or other drugs and procedures in severe cases of the following diseases, in patients who are intolerant to steroids or who are dependent on steroids and in whom the therapeutic response is inadequate despite treatment with high doses of steroids:
|
Strengths | 50mg film-coated Tablet |
Business Partner | Mylan |
Origin | India |
Related Products
Related products
OLISENS (Aganirsen)
Rated 0 out of 5Ciclograft: (Cyclosporine 2%)
Rated 0 out of 5XIAFLEX (Collagenase Clostridium Histolyticum)
Rated 0 out of 5Irofin®(Deferiprone) – 500 mg
Rated 0 out of 5
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.